Venture Global Inc. Class A common stock vs Vir Biotechnology Inc. Common Stock — how do they compare? Venture Global Inc. Class A common stock trades at $13.22 (market cap $34.60B), while Vir Biotechnology Inc. Common Stock trades at $10.2 (market cap $1.80B). The key difference: Venture Global Inc. Class A common stock is far larger — about 19.2× Vir Biotechnology Inc. Common Stock's market cap, and Venture Global Inc. Class A common stock pays a 1.16% dividend while Vir Biotechnology Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Venture Global Inc. Class A common stock for 1 Days and Vir Biotechnology Inc. Common Stock for 0 Days on average.
| VG | VIR | |
|---|---|---|
Market Cap | $34.60B | $1.80B |
Volume | 11,731,839 | 1,782,836 |
Sector | Energy | Health |
52-Week High | $17.53 | $11.78 |
52-Week Low | $5.92 | $5.12 |
Typical Hold Time | 1 Days | 0 Days |
Enterprise Value | $73.99B | $1.36B |
Dividend Yield | 1.16% | — |
Signals from Pluang's Aura AI — not financial advice
VG trades at $13.84, up 5.41% today, with a bearish technical signal but strong fundamentals including a 21.24% net income margin and 48.13% ROE. Recent earnings have consistently beaten estimates, and the company is expanding LNG capacity to 85 MTPA by 2029, supported by long-term supply deals like the 20-year agreement with ConocoPhillips announced on October 1, 2026.
The stock offers value with a P/E of 10.52 and consensus price target of $16.13, but faces risks from high short interest and negative net cash flow in 2025. Analyst sentiment is bullish with 58% buy ratings, though technical indicators suggest near-term caution.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Venture Global develops, builds, and operates liquefied natural gas export facilities. Its projects connect U.S. natural gas supply with global LNG markets.
Read more on VG →Vir Biotechnology, Inc. is a US clinical-stage biopharmaceutical company that develops monoclonal antibody-based medicines to treat and prevent serious infectious diseases.
Read more on VIR →